Financing Will Support FIH Clinical Evaluation of InnovHeart’s Saturn TMVR System

August 7, 2020—InnovHeart s.r.l., a developer of transcatheter mitral valve replacement (TMVR) systems for the treatment of mitral valve disease, announced the closing of a €20 million round of equity financing.

According to the company, proceeds from the financing will be used to complete the first-in-human clinical evaluation of the company’s Saturn TMVR system using a transapical approach. The round will also allow InnovHeart to finalize the development of the transseptal delivery system, which uses the same Saturn valve technology.

Founded in 2015 by Giovanni Righini, InnovHeart has offices outside Milan, Italy, and Boston, Massachusetts. Keith D. Dawkins, MD, is Chairman of the InnovHeart Board of Directors. Dr. Dawkins was Executive Vice President and Global Chief Medical Officer of Boston Scientific.

The Series B round was raised from existing investor Genextra, which has been the sole investor since 2015, and a syndicate led by Panakes Partners, with CDP Venture Capital and Indaco Venture Partners.